U.S. Professional Services Stock News

If you are trying to work out whether DraftKings stock looks attractively priced or too expensive at today’s levels, you will want more than just the latest share price in front of you. The stock recently closed at US$25.22, with returns of 8.1% over 7 days and 9.9% over 30 days, while year to date and 1 year returns of negative 29.3% and negative 28.7% show a very different picture over a longer window. Recent headlines around DraftKings have largely focused on the broader US sports betting...

For investors wondering if Krystal Biotech at around US$296.70 is still offering value or if the easy gains are behind it, this article walks through what the current price may be implying. The stock has shown strong share price moves, with returns of 13.1% over 7 days, 12.4% over 30 days, 20.2% year to date, 116.3% over the last year, 228.5% over 3 years, and 374.4% over 5 years. These price moves sit against a backdrop of ongoing attention on Krystal Biotech's position in the...

Gibraltar Industries (ROCK) opened Q1 2026 with total revenue of US$356.3 million and a basic EPS loss of US$0.40, setting a cautious tone around the latest numbers. The company has seen quarterly revenue move from US$246.4 million and EPS of US$0.76 in Q1 2025 through a series of US$309.5 million to US$310.9 million quarters with EPS between US$0.99 and US$1.12, before landing at US$268.7 million and EPS of US$0.40 in Q4 2025. This gives investors a clear look at how the top line has...

Wondering if Sigma Lithium's current share price reflects its true worth, or if the recent excitement has run ahead of the fundamentals? The stock last closed at US$23.65, with returns of 7.2% over 7 days, 61.7% over 30 days, 66.4% year to date, 218.7% over 1 year and 401.5% over 5 years, while the 3 year return stands at a loss of 40.0%. Recent coverage has focused on Sigma Lithium as a lithium producer, with investors watching how sentiment around the sector and the company's development...

Eversource Energy (ES) opened 2026 with Q1 revenue of about US$4.5 billion and basic EPS of US$1.61, setting the stage against a year of sharply higher trailing earnings and wider margins. Over the last six reported quarters, quarterly revenue has ranged from US$2.8 billion to US$4.5 billion while basic EPS has moved between roughly US$0.20 and US$1.61, and on a trailing twelve month basis EPS reached US$4.69 alongside revenue of about US$13.9 billion. With trailing net margin sitting above...

N-able (NABL) has opened 2026 with Q1 revenue of US$133.7 million and a basic EPS loss of US$0.00, alongside net income excluding extraordinary items of a US$0.6 million loss, setting a mixed tone for the latest results. Over recent quarters the company has seen revenue move from US$118.2 million in Q1 2025 to US$133.7 million in Q1 2026, while basic EPS has shifted between a profit of US$0.01 in Q3 2025 and a larger loss of US$0.04 in Q4 2025 before this latest small loss per share. For...

If you are wondering whether Qnity Electronics at around US$143.59 is richly priced or still offers value, this breakdown outlines what the current share price might be implying. The stock has returned 2.1% over the last 7 days, 20.7% over the past month, and 69.0% year to date, which has put valuation squarely on investors' radar. Recent coverage has focused on Qnity Electronics' position within the semiconductor sector and how investors are reassessing companies tied to data infrastructure...

TKO Group Holdings (TKO) opened 2026 with Q1 revenue of about US$1.6b and basic EPS of US$1.16, alongside trailing 12 month EPS of US$2.84 on revenue of roughly US$5.1b and net income of US$226.35m, setting a clear marker for how the business is currently earning. Over recent quarters, revenue has moved from US$927.92m in Q4 2024 to US$1.27b in Q1 2025 and then to US$1.60b in Q1 2026. Quarterly basic EPS has ranged from US$0.38 in Q4 2024 to US$0.72 in Q1 2025 and US$1.16 in Q1 2026, giving...

If you are wondering whether York Space Systems is fairly priced or offering an opportunity at current levels, the next sections break down what the numbers suggest about value. The stock recently closed at US$33.38, with returns of 0.7% over the past week, 21.1% over the last 30 days, and a small year to date decline of 0.7%. This may catch the eye of investors watching for a turning point in sentiment. Recent attention around York Space Systems has focused on its position in the space and...

If you are wondering whether CenterPoint Energy at around US$42.24 is offering good value today, it helps to separate the story, the share price moves and what the numbers actually say. The stock has a 9.1% return year to date, 13.9% over 1 year and 96.0% over 5 years, even though the last 7 and 30 days show returns of 3.2% and 3.1% declines. This means recent moves may feel very different from the longer term picture. Recent coverage has focused on CenterPoint Energy as a regulated utility...

AppLovin (APP) has opened 2026 with Q1 revenue of US$1.8 billion and basic EPS of US$3.57, setting the tone for its latest earnings season update. The company has seen quarterly revenue move from US$1.0 billion in Q4 2024 to US$1.2 billion in Q1 2025 and then to US$1.8 billion in Q1 2026. Basic EPS over the same points stepped from US$1.76 to US$2.13 and then to US$3.57, giving investors a clear view of scaling revenue alongside higher earnings per share as margins stay in focus. See our full...

Rackspace Technology (RXT) opened 2026 with Q1 revenue of US$678.1 million and basic EPS of US$0.03, compared to a trailing 12 month basic EPS loss of US$0.60 on revenue of US$2.7 billion. The company has seen quarterly revenue move from US$685.6 million in Q4 2024 to US$665.4 million in Q1 2025 and US$678.1 million in Q1 2026. Basic EPS shifted from a loss of US$0.25 in Q4 2024 to a loss of US$0.31 in Q1 2025 and then to a small profit in the latest quarter. This sets up a results season...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical milestones across several AI-driven drug programs. REC-1245 showed encouraging early safety data in humans. Patient dosing has started for REC-4539, moving another asset into active clinical testing. REC-4881 produced meaningful efficacy signals in familial adenomatous polyposis, prompting engagement with the FDA about a potential registrational path. For investors watching NasdaqGS:RXRX, these program updates focus...

Solstice Advanced Materials (SOLS) opened 2026 with Q1 revenue of US$992 million and basic EPS of US$0.54, giving investors a fresh look at its earnings power after a volatile prior year. Over recent quarters the company has seen revenue move from US$897 million in Q1 2025 to US$969 million in Q3 2025, US$987 million in Q4 2025 and now US$992 million in Q1 2026. Quarterly basic EPS has ranged from a loss of US$0.22 in Q3 2025 to US$0.84 in Q1 2025 and US$0.26 in Q4 2025 before landing at...

Investors may naturally wonder whether Nebius Group at US$184.77 is now priced for perfection or still offers room for value after such a strong run. The stock has posted returns of 33.7% over the past week, 57.4% over the past month and 105.4% year to date, with a very large 1 year gain that may have shifted how investors view both its potential and its risks. Recent coverage has focused on Nebius Group's sharp share price moves and what they might imply about sentiment toward its business...

Shareholders might have noticed that XPEL, Inc. ( NASDAQ:XPEL ) filed its quarterly result this time last week. The...

It looks like ConocoPhillips ( NYSE:COP ) is about to go ex-dividend in the next two days. The ex-dividend date is...

Last week saw the newest quarterly earnings release from Haverty Furniture Companies, Inc. ( NYSE:HVT ), an important...

Stevanato Group (NYSE:STVN) opened 2026 with Q1 revenue of €273.6 million and basic EPS of €0.10, alongside trailing 12 month revenue of about €1.2 billion and EPS of €0.52 that frame the latest quarter against a fuller earnings backdrop. Over recent periods, revenue has ranged from €256.6 million in Q1 2025 to €346.5 million in Q4 2025, while basic EPS has moved between €0.10 and €0.17 across those quarters, giving investors a clear view of how the top and bottom lines are tracking into the...

Curtiss-Wright (CW) opened 2026 with Q1 revenue of US$913.7 million and Basic EPS of US$3.47, while trailing twelve month revenue sat at about US$3.6 billion with EPS of US$13.73 and net income of US$511.1 million. Over the last five reported quarters, revenue has moved from US$805.6 million in Q1 2025 to US$913.7 million in Q1 2026, with Basic EPS over that span ranging between US$2.69 and US$3.71. With trailing net profit margin edging higher over the past year, these results give investors...

Primerica (PRI) opened 2026 with Q1 revenue of US$885.9 million and basic EPS of US$6.00, supported by net income of US$190.1 million and a combined ratio of 65.2%, setting a clear tone for how the year is starting. The company has seen quarterly revenue move from US$803.4 million in Q4 2024 to US$819.5 million in Q1 2025 and then to US$885.9 million in Q1 2026. Over that period, basic EPS ranged from US$4.99 to US$6.36, pointing to a business that is still generating meaningful profits as...

Mueller Water Products (NYSE:MWA) has flagged a higher priority on acquisitions, with management highlighting more active work on potential targets. The company is planning to use its balance sheet and increased M&A readiness to expand its portfolio and support net sales growth. This marks a shift in capital allocation focus toward deals that could reshape its market presence and operating profile. Mueller Water Products focuses on water infrastructure products and services, an area that...

Chubb (NYSE:CB) has formed an alliance with Verified Clinical Trials to support risk management and data quality in clinical research. The partnership focuses on research subject safety, data integrity, and reducing operational and regulatory risks using VCT's subject registry technology. This development extends Chubb's activity beyond traditional insurance coverage into technology driven clinical trial risk solutions. For investors tracking Chubb at a current share price of $321.28, the...

Wondering if Intellia Therapeutics at around US$13.71 is offering value or just volatility? This article walks through what the current price may be implying about the stock. The stock has returned 1.7% over the last 7 days, 1.2% over 30 days, 48.9% year to date and 65.6% over the past year, while longer term 3 year and 5 year returns of 69.3% and 77.5% declines show how sentiment around the stock has shifted over time. Recent headlines around Intellia Therapeutics have focused on its...